Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: Before or after tuberculosis diagnosis?

AIDS

Volumn 25, Issue 7, 2011, Pages 1003-1006

  Kerkhoff, Andrew D ^a,b   Wood, Robin ^a   Lawn, Stephen D ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BACTERIUM CULTURE; DELAYED DIAGNOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING; SOUTH AFRICA; THERAPY DELAY; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 79954802717     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328345ee32     Document Type: Article

References (21)

1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
2. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
3. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51:135-139.
4. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral ser-vice in South Africa: implications for programme design. AIDS 2005; 19:2141-2148. (Pubitemid 41669003)
5. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612. (Pubitemid 44162402)
6. Lawn SD, Torok ME, Wood R. Optimum time to start anti-retroviral therapy during HIV-associated opportunistic infec-tions. Curr Opin Infect Dis 2011; 24:34-42.
7. Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosup-pressed HIV-infected adults with newly diagnosed tuberculosis [abstract THLBB1]. In: Programs and Abstracts of the 18th International AIDS Conference; 18-23 July 2010; Vienna, Austria. Vienna: International AIDS Society; 2010.
8. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 revision). Geneva: WHO Press 2010. pp. 1-145. http://www.who.int/hiv/pub/arv/ adult/en/index.html. [Accessed 19 December 2010]
9. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011, in press.
10. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875 1880.
11. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretro-viral therapy in a South African cohort using an inten-sive pretreatment screening strategy. AIDS 2010; 24:1323-1328.
12. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al. Intensivetuberculosisscreeningfor HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-829.
13. World Health Organization. Improving the diagnosis and treat-ment of smear-negative pulmonary and extrapulmonary tuber-culosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. Geneva: WHO Press; 2007. pp. 1-36. WHO/HTM/2007.379 & WHO/HIV/2007.1. http://whqlibdoc.who.int/hq/2007/WHO- HTM-TB-2007.379-eng.pdf.
14. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune recon-stitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177:680-685. (Pubitemid 351490554)
15. Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003; 79:337-338. (Pubitemid 37026357)
16. Lawn SD, Wainwright H, Orrell C Fatal unmasking tubercu-losis immune reconstitution disease with bronchiolitis obliter-ans organizing pneumonia: the role of macrophages. AIDS 2009; 23:143-145.
17. KoenigSP, RiviereC, Leger P, Joseph P, Severe P, Parker K, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48:829-831.
18. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-1725.
19. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconsti-tution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516-523. (Pubitemid 352005824)
20. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341. (Pubitemid 46175045)
21. BoehmeCC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N EnglJ Med 2010; 363:1005-1015.